Key Highlights

  • Cerebras (NASDAQ:CBRS) rebounded about 10 percent to near USD 184 on October 5, 2026, close to its USD 185 IPO price of May 13, after hitting a post-IPO low during a week that fell roughly 20 percent.
  • Remaining performance obligations were USD 25.4 billion at June 30, 2026, and second-quarter GAAP Revenue was USD 180.1 million, up 74 percent, with a GAAP net loss of USD 450.5 million.
  • A lockup expiry made about 19.4 million shares eligible for sale around September 30, while Form 144 notices showed intended sales by the chief operating officer and chief financial officer.
  • Liquidity was USD 8.6 billion, and UBS keeps a Buy rating with a USD 330 target, against a first-day close of USD 311.07 on May 14.

A Rebound After a Brutal Week

Cerebras (NASDAQ:CBRS) listed on Nasdaq on May 14, 2026 after pricing 30 million shares at USD 185, raising USD 5.55 billion, and closed its first day at USD 311.07. On September 30 it fell 8.87 percent to USD 177.65 as a lockup ended and a research firm, SemiAnalysis, reported that OpenAI's newest ultrafast model runs on standard GPUs rather than Cerebras systems, a report the company has not confirmed. Two executives filed Form 144 notices for about USD 77.9 million (chief operating officer) and USD 6.39 million (chief financial officer) of stock. The shares reached a post-IPO low on October 2, then rebounded about 10 percent on October 5 to near USD 184 in published market data, without a company announcement identified.

Backlog, Losses and Concentration

The August 12 second-quarter report showed GAAP revenue of USD 180.1 million, up 74 percent, and GAAP cloud revenue of USD 126.0 million, up 281 percent. Core revenue was USD 209.9 million, up 103 percent. GAAP gross Margin was 14 percent and core gross margin 41 percent. The GAAP net loss was USD 450.5 million and Liquidity USD 8.6 billion. Remaining performance obligations, contracted revenue not yet recognized, were USD 25.4 billion. Full-year core revenue guidance is USD 880 million to USD 890 million, and third-quarter core gross margin is guided to 38 percent to 40 percent. Much of the Backlog depends on OpenAI, which reportedly signed a deal worth about USD 10 billion through 2028.

Risks and What to Watch

Customer concentration is the first risk: if OpenAI shifts workloads to Nvidia hardware, backlog conversion could slow. Second, further lockup-related selling and insider sales can pressure the price. Third, losses are deep, with the GAAP net loss more than double quarterly revenue. UBS rates the shares Buy with a USD 330 target, a view not shared by all analysts. The stock has traded well below its first-day close of USD 311.07. Watch the third-quarter report, with a date not yet confirmed, for margin recovery, the OpenAI capacity ramp and cloud growth. Single-stock risk is high relative to the Nasdaq-100, and a weak tape for AI hardware could compound it.

Where Things Stand

It is Cerebras (NASDAQ:CBRS). The AI chipmaker, with USD 25.4 billion of contracted backlog, rebounded about 10 percent to near its USD 185 IPO price on October 5 after a lockup-driven slide and OpenAI concerns. Deep losses, customer concentration and insider selling remain, and the backlog gives the bull case its anchor, while the next Quarterly Report will show whether margins recover and whether OpenAI Demand holds.